651 related articles for article (PubMed ID: 19169242)
41. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer.
Watkins DN; Berman DM; Burkholder SG; Wang B; Beachy PA; Baylin SB
Nature; 2003 Mar; 422(6929):313-7. PubMed ID: 12629553
[TBL] [Abstract][Full Text] [Related]
42. Targeting the hedgehog signaling pathway with small molecules.
Kiselyov AS
Anticancer Agents Med Chem; 2006 Sep; 6(5):445-9. PubMed ID: 17017853
[TBL] [Abstract][Full Text] [Related]
43. The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia.
Wu A; Turner KA; Woolfson A; Jiang X
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986819
[TBL] [Abstract][Full Text] [Related]
44. Advances in Smoothened-targeting therapies for pancreatic cancer: implication for drug discovery from herbal medicines.
Han JB; Hua YQ; Chen LY; Liu LM
Zhong Xi Yi Jie He Xue Bao; 2012 Mar; 10(3):256-63. PubMed ID: 22409914
[TBL] [Abstract][Full Text] [Related]
45. Hedgehog signaling is dispensable for adult hematopoietic stem cell function.
Gao J; Graves S; Koch U; Liu S; Jankovic V; Buonamici S; El Andaloussi A; Nimer SD; Kee BL; Taichman R; Radtke F; Aifantis I
Cell Stem Cell; 2009 Jun; 4(6):548-58. PubMed ID: 19497283
[TBL] [Abstract][Full Text] [Related]
46. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.
Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M
FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740
[TBL] [Abstract][Full Text] [Related]
47. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
[TBL] [Abstract][Full Text] [Related]
48. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
49. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
[TBL] [Abstract][Full Text] [Related]
50. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
[TBL] [Abstract][Full Text] [Related]
51. Targeting of Smoothened for therapeutic gain.
Ruat M; Hoch L; Faure H; Rognan D
Trends Pharmacol Sci; 2014 May; 35(5):237-46. PubMed ID: 24703627
[TBL] [Abstract][Full Text] [Related]
52. Sonic hedgehog signalling pathway regulates apoptosis through Smo protein in human umbilical vein endothelial cells.
Zhu SL; Luo MQ; Peng WX; Li QX; Feng ZY; Li ZX; Wang MX; Feng XX; Liu F; Huang JL
Rheumatology (Oxford); 2015 Jun; 54(6):1093-102. PubMed ID: 25406358
[TBL] [Abstract][Full Text] [Related]
53. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
54. Drosophila Vps36 regulates Smo trafficking in Hedgehog signaling.
Yang X; Mao F; Lv X; Zhang Z; Fu L; Lu Y; Wu W; Zhou Z; Zhang L; Zhao Y
J Cell Sci; 2013 Sep; 126(Pt 18):4230-8. PubMed ID: 23843610
[TBL] [Abstract][Full Text] [Related]
55. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
[TBL] [Abstract][Full Text] [Related]
56. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
Gwanmesia PM; Romanski A; Schwarz K; Bacic B; Ruthardt M; Ottmann OG
BMC Cancer; 2009 Feb; 9():53. PubMed ID: 19216789
[TBL] [Abstract][Full Text] [Related]
57. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
Burslem GM; Schultz AR; Bondeson DP; Eide CA; Savage Stevens SL; Druker BJ; Crews CM
Cancer Res; 2019 Sep; 79(18):4744-4753. PubMed ID: 31311809
[TBL] [Abstract][Full Text] [Related]
58. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
59. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
60. Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
Liao HC; Chou YJ; Lin CC; Liu SH; Oswita A; Huang YL; Wang YL; Syu JL; Sun CM; Leu CM; Lin CH; Fu SL
Biochem Pharmacol; 2019 May; 163():308-320. PubMed ID: 30822403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
